BioSpace News Archive

Pasithea Therapeutics Corp. announced that its meeting of stockholders, which had been partially adjourned on December 19, 2023, was reconvened on December 28, 2023 and then was further adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the charter amendment proposals included as Proposals 4, 5, 5 and 5 in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on October 26, 2023.

Jiangsu Recbio Technology Co., Ltd. is pleased to announce that the novel adjuvanted recombinant shingles vaccine REC610 independently developed by the Company has recently achieved positive results in the interim analysis of first-in-human clinical trial in the Philippines.

Apellis Pharmaceuticals, Inc. announced that the company will host a fireside chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference on Thursday, January 4, 2023, at 2:25 p.m. ET.

Sequana Medical NV announces that it has submitted a Premarket Approval application to the US Food and Drug Administration for alfapump, the Company’s fully implantable, wirelessly charged device for patients with recurrent or refractory ascites due to liver cirrhosis.

Developing brains become shaped by the sights, sounds, and experiences of early life. The brain’s circuits grow more stable as we age.

MediWound Ltd. announced that the U.S. Department of Defense, through the Medical Technology Enterprise Consortium, has awarded MediWound an additional $6.7 million in non-dilutive funding to develop NexoBrid® as a non-surgical solution for field-care burn treatment for the U.S. Army.

Bluejay Diagnostics, Inc. announced the pricing of a public offering of 2,692,308 shares of the Company’s common stock and warrants to purchase up to 2,692,308 shares of common stock at a combined offering price of $1.30 per share and associated warrant.

ChemDiv announces a strategic collaboration with the University of Texas Medical Branch to facilitate the expansion of its inventory and advance the institution’s High-throughput Screening research programs.

Enveric Biosciences announced that it has named EB-003 as its lead drug candidate from the Company’s next-generation EVM301 Series.

Shanghai Henlius Biotech, Inc. announces that recently, PT Kalbio Global Medika, the subsidiary of Henlius’ partner PT Kalbe Genexine Biologics, has received the relevant registration certificates issued by Indonesia’s National Agency for Drug and Food Control for the approval of Henlius’ self-developed and manufactured anti-PD-1 mAb HANSIZHUANG in Indonesia under the trade name Zerpidio® for the treatment of extensive stage small cell lung cancer.